Sea Pharmaceuticals announces strategic relationship with Inotiv

Sea Pharmaceuticals announced its selection of Inotiv (NOTV) for pre-clinical development IND-enabling studies to support the advancement of Sea’s lead molecule SPM-0404 as a potential new oral medicine to treat tinnitus, epilepsy and S-ALS. Sea’s SPM-0404 and a second-generation molecule SPM-0606 represent a portfolio strategy of discovery and development of potent, selective, CNS-penetrant molecules targeting excitatory glutamate neurotransmission. A 100% Sea-owned patent estate protects Sea’s novel chemical composition of matter in separate filings.